



The 41st Annual
High Country
Nuclear
Medicine
Conference

March 7-11, 2020
Sun Valley Inn | Sun Valley, ID

Saturday, March 7, 2020

6:30 am – 7:00 am

Breakfast with the Vendors

7:00 am – 9:30 am

Imaging the Immune System for Personalized Medicine, Immuno-oncology
Session Organizer: Michael Devous, PhD

Scheduled Topics:

Utility of Imaging In Immunotherapy

Speaker: Michael Graham, MD

Treatment Response Criteria in the Era of Immunotherapy

Speaker: Hossein Jadvar, MD, PhD

New Approaches to Imaging the Immune System

Speaker: Hartmuth Kolb, PhD

1:00 pm – 3:00 pm

Roundtable Discussion: Dosimetry and Therapy Planning
Moderator: Hans Vija, PhD

4:00 pm – 7:30 pm

Amino Acid PET for Neuro-Oncology: Current Status and Opportunities
Session Organizer: Jonathan McConathy, MD, PhD

Scheduled Topics

Overview of molecular imaging for neuro-oncology

Speaker: Jonathan McConathy, MD, PhD

Current techniques for clinical brain tumor imaging

Speaker: Derek Johnson, MD

FDOPA for adult and pediatric neuro-oncology

Speaker: Maria Rosana Ponisio, MD

Fluciclovine for neuro-oncology

Speaker: Ephraim Parent, MD, PhD

Panel Discussion

Sunday, March 8, 2020

6:30 am – 7:00 am

Breakfast with the Vendors

7:00 am – 9:30 am

ISCHEMIA Trial: Results, Implications, and Challenges

Session Organizer: Daniel Berman, MD

Scheduled Topics

A Deep Dive into the Results

Speaker: Leslee Shaw, PhD

Trial Strengths and Limitations

Speaker: Panithaya Chareonthaitawee, MD

Role of Absolute MBF in the post-ISCHEMIA Trial Era

Speaker: Venkatesh Murthy, MD, PhD

Implications for Nuclear Cardiology and Coronary CTA

Speaker: Daniel Berman, MD

Addressing Trial Results Locally

Speaker: Robert Hendel, MD

Challenges for Nuclear Cardiology: Open Panel Discussion

1:00 pm – 3:00 pm

Roundtable Discussion: Regulatory Session

Moderator: Ira Goldman, MA

4:00 pm – 6:30 pm

Neuroimaging of Tauopathy and Inflammation

Session Organizers: Alan Packard, PhD and Daniel Silverman, MD, PhD, Conference Chair

In a session that focuses on imaging of tau-based proteinopathy and inflammatory processes in living human brain, we will cover: 1. How the latest imaging-derived data informs the related neuroscience, and corresponding neurologic work-up (diagnosis,/prognosis, image-guided therapy, etc.), and 2. What is on the near-future horizon with respect to developing commercially viable radiotracers having potential clinical utility, particularly with respect to TBI/CTE and dementia-related disorders.

Presenters and Topics

Tau

Neuroimaging of Tau: Progress towards Understanding Traumatic Brain Injury (TBI) and Chronic Traumatic Encephalopathy (CTE)

Speaker: TBD

Neuroimaging of Tau: Progress towards Understanding non-AD Neurodegenerative Diseases

Speaker: Andrew Stephens, Life Molecular Imaging

Tau Imaging Radiotracers: Path towards Validation and Commercialization

Speaker: TBD

Neuroinflammation

Neuroimaging of Inflammation: Progress towards Understanding TBI, CTE and MCI

Speaker: TBD

Inflammation Neuroimaging: Path towards Validation and Commercialization of Radiotracers

Speaker: Mike Devous, Avid Radiopharmaceuticals

Past, Present and Future of Imaging TBI, CTE, MCI, AD and Related Disorders

Panel Discussion and Global Q&A

Panelists: Mike Devous, Andrew Stephens, Alan Packard, Dan Silverman, Hartmuth Kolb

7:00pm – 10:00pm

Dinner

Monday, March 9, 2020

6:30 am – 7:00 am

Breakfast with the Vendors

Monday March 9, 2020

7:00 am – 9:30 am

Legislative and Regulatory Update

Session Chair: Ira Goldman, MA

2019 witnessed considerable legislative and executive branch activity related to healthcare at both the U.S. Federal and State levels. With Democrats in control of the U.S. House of Representatives there are new battles shaping up over the Affordable Care Act initiated during the Obama Administration. With a Presidential election already underway, drug pricing was one of the rare areas in which both U.S. political parties agreed that action is necessary, and there was a flurry of legislation related to drug price transparency and negotiations, promotion/facilitation of generic drugs (including changes to the drug patent regime), and “surprise” medical billing. Although PAMA and MACRA become increasingly distant memories, Appropriate Use Criteria (AUC) and Clinical Decision-Support (CDS) efforts continue to progress. Major gaps in coverage and payment continue to challenge the future of nuclear medicine. This session will provide updates regarding an overview of ongoing legislative and regulatory changes impacting the nuclear medicine sector.

Presenters and Topics

SNMMI Initiatives – President’s Report on Current and Future Directions

Speaker: Dr. Vasken Dilsizian, MD, PhD, SNNMI

Nuclear Medicine Opportunities and Challenges in Washington during a Presidential Election Year

Speaker: Sue Bunning, Industry Director, Positron Emission Tomography, Medical Imaging and Technology Alliance

Status Report on FDA Review of Radiopharmaceutical/Theranostics

Speaker: Lou Marzella, MD, PhD, FDA

Reimbursement – Coverage, Payment and Coding

Speaker: Denise Merlino

Appropriate Use Criteria – What’s New, What’s Revised? - Thyroid and Prostate Cancer, Infection Imaging, etc.

Speaker: Kevin Donohoe, MD

Panelists: Dr. Vasken Dilsizian, Sue Bunning, Lou Marzella, Kevin Donohoe, and Denise Merlino

1:00 pm – 3:00 pm

Roundtable Discussion: Adding value to Cardiac PET using MFR and MBF: A case-based approach

Moderators: Ernie Garcia, PhD and Val Lowe, MD

Speaker: Venkatesh Murthy, MD, PhD

4:00 pm – 7:30 pm

Advancing Technology AI and Instrumentation

Session Organizers: Ernie Garcia, PhD and Val Lowe, MD

The Artificial Intelligence (AI) portion of this session describes the tools as well as the similarities and differences in the subfields of AI that include decision support systems, machine learning and deep learning. Examples of applications in nuclear medicine are presented. The challenges and opportunities in the future of these important tools will be discussed.

Presenters and Topics

Brief Primer on AI with Imaging Applications

Speaker: Ernie Garcia, PhD

Advanced Imaging Applications with Deep Learning and Big Data

Speaker: Piotr Slomka, PhD

How Long is Long Enough: Long Bore Scanner Physics

Speaker: Bernard Bendriem, PhD

Digital Detectors and Their Transformative Effect on PET Scanner Design and Performance

Speaker: Joel Karp, PhD

Clinical Applications with Long Bore Scanner Technology

Speaker: Val J. Lowe, MD

6:30 am – 7:00 am

Breakfast with the Vendors

7:00 am – 9:30 am

Emerging Topics in Pediatrics

Session Organizers: Barry Shulkin and Alan Packard, PhD

Session Description: This session will feature a range of topics related to pediatric nuclear medicine with a focus on what's new: new imaging agents, new radiotherapeutics, new methodology, and new ways to use established tracers.

Scheduled Topics:

[¹⁸F]mFGB and Neuroblastoma

Speakers: Neeta Pandit-Taskar, MD

^{64/67}Cu-SARTATE as a Theranostic for the Treatment of Neuroblastoma

Speaker: Colin Biggin, PhD

[¹⁸F]FPEB Imaging in Adolescent Depression and Suicide

Speakers: Irina Esterlis PhD

FDG PET/CT Radiomics in Childhood/Adolescent/Young Adult Osteosarcoma

Speakers: Steve Cho, MD

PET/MRI in Pediatrics

Speakers: Helen Nadel, MD

¹³¹I-3F8 for the Treatment of Brain Stem Gliomas

Speakers: Neeta Pandit-Taskar, MD

FDOPA in pediatric hyperinsulinism: The road to an NDA

Speakers: Maria Rosana Ponisio, MD

Panel Discussion and Q&A

1:00 pm – 3:00 pm

Roundtable Discussion: Industry – Current Highlights, Unmet Needs, Future Innovations

Description: Technology and tracers in the realm of multi-modality imaging; timing and perceived clinical need is often the biggest factor in success or failure. With this session we'll work to "see around the corners" of the role of radionuclide imaging in addressing the biggest healthcare problems.

Moderators: Edward L. Lyons, RT, CNMT

4:00 pm – 7:30 pm

Neuroendocrine Imaging (e.g., Ge-68 Dotatate, Ga-68 Dotatoc and Cu-64 Dotatate)

Session Organizers: Andreas Kjaer, MD, PhD and Roy Brown, BS, MBA

Description: Following the Novartis acquisition of AAA and Endocyte, pharma has increased their interest in targeted radionuclide therapy. The pipeline is increasing both academically and commercially. Potential speakers from academia and companies as Endocyte, AAA, Bayer, Actinium pharmaceuticals, Nordic Nanovector, 3B pharmaceuticals, clarity pharmaceuticals etc.

Scheduled Topics:

Targeted Radiopharmaceuticals

Next Generation

FDA considerations

Wednesday, March 11, 2020

6:30 am – 7:00 am

Breakfast with the Vendors

7:00 am – 9:30 am

Thyroid / Endocrinology

Session Organizer: Michael Wissmeyer, MD

Scheduled Topics:

Status of New or Updated Appropriate Use Criteria (AUC)

Controversies in Low Dose Anlation of DTC

F18-DOPA PET in Medullary Thyroid Cancer

Speakers: Claire Tabouret, MD

F18-Choline PET in Parathyroid Adenomas

Speakers: Michael Wissmeyer, MD